Clinical Advantage Position Selux NGP as a rapid, precise diagnostic platform that can shorten time to targeted therapy by up to several days, enabling hospitals to reduce broad-spectrum antibiotic use and improve patient outcomes.

Hospital Partnerships Target large health systems and academic medical centers with ARR/PMF-like value propositions, leveraging BARDA-era funding experience and FDA pivotal trial momentum to secure multi-site collaborations.

AMR Commitment Highlight alignment with antimicrobial resistance (AMR) containment goals and CDC concerns to engage government-funded opportunities and grant-driven pilots in infectious disease management.

Funding Momentum Capitalize on recent multi-project funding rounds and convertible debt financings to approach prospective investors and co-development partners for expanded clinical validation and commercialization efforts.

Executive Access Leverage board and leadership connections, including recent board hires and C-suite appointments, to open doors with strategic buyers and accelerate contract negotiations for preferred access to the NGP platform.